Not Again: Benzodiazepines Once More under Attack

Journal of Clinical Psychopharmacology

Volumn 35, Issue 5, 2015, Pages 493-495

  Salzman, Carl ^a   Shader, Richard I ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT;

ANXIETY DISORDER; BALANCE IMPAIRMENT; BENZODIAZEPINE DEPENDENCE; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; EDITORIAL; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNSTEADINESS; WITHDRAWAL SYNDROME; FEMALE; MALE; STATISTICS AND NUMERICAL DATA;

BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE;

EID: 84941267776     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000383     Document Type: Editorial

References (17)

1. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328:1398-1405.
2. Mellinger GD, Balter MB, Uhlenhuth EH, et al. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA. 1984;251:375-379.
3. Balter MB, Levine J, Manheimer DI. Cross-national study of the extent of anti-anxiety/sedative drug use. N Eng JMed. 1974;290:769-774.
4. Salzman C. Benzodiazepine Dependency, Toxicity and Abuse. Washington, DC: American Psychiatric Association; 1990.
5. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72:136-142.
6. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry. 2003;160:1432-1438.
7. Moore N, Pariente A, Begaud B. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry. 2015;72:110-111.
8. Salzman C. Treatment of anxiety and anxiety-related disorders. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;449-482.
9. Barker MJ, Greenwood KM, Jackson M, et al. An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychohol. 2005;11:281-281.
10. Bierman EJM, Comijs HC, Gundy CM, et al. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatric Psychiatry. 2007;22:1194-1200.
11. Salzman C, Fiisher J, Nobel K, et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriat Psychiatry. 1992;7:89-93.
12. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952-1960.
13. de Gage SB, Moride LY, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ. 2014;349:205.
14. Salzman C, Shader RI. Benzodiazepine use and risk for Alzheimer disease. J Clin Psychopharmacol. 2015;35:1-2.
15. Lasagna L, Shader RI. Awhite paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics. J Clin Pharmacol. 1994;34:812-815.
16. Ross-Degnan D, Simoni-Wastila L, Brown J, et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med. 2004;4:103-123.
17. Weintraub M, Singh S, Byrne L, et al. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA. 1991;266:2392-2397.